SI113, a Specific Inhibitor of the Sgk1 Kinase Activity that Counteracts Cancer Cell Proliferation
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background/Aims: Published observations on serum and glucocorticoid regulated kinase 1 (Sgk1) knockout murine models and Sgk1-specific RNA silencing in the RKO human colon carcinoma cell line point to this kinase as a central player in colon carcinogenesis and in resistance to taxanes. Methods: By in vitro kinase activity inhibition assays, cell cycle and viability analysis in human cancer model systems, we describe the biologic effects of a recently identified kinase inhibitor, SI113, characterized by a substituted pyrazolo[3,4-d]pyrimidine scaffold, that shows specificity for Sgk1. Results: SI113 was able to inhibit in vitro cell growth in cancer cells derived from tumors with different origins. In RKO cells, this kinase inhibitor blocked insulin-dependent phosphorylation of the Sgk1 substrate Mdm2, the main regulator of p53 protein stability, and induced necrosis and apoptosis when used as a single agent. Finally, SI113 potentiated the effects of paclitaxel on cell viability. Conclusion: Since SI113 appears to be effective in inducing cell death in RKO cells, potentiating paclitaxel sensitivity, we believe that this new molecule could be efficiently employed, alone or in combination with paclitaxel, in colon cancer chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell surface protein glycosylation in cancer
Christiansen, M. N., Chik, J., Lee, L., Anugraham, M., Abrahams, J. L., & Packer, N. H. (2014) · PROTEOMICS · doi:10.1002/pmic.201300387 · Cited by 518
Sherk, A. B., Frigo, D. E., Schnackenberg, C. G., Bray, J. D., Laping, N. J., Trizna, W., Hammond, M., Patterson, J. R., Thompson, S. K., Kazmin, D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1047 · Cited by 211
Amato, R., D’Antona, L., Porciatti, G., Agosti, V., Menniti, M., Rinaldo, C., Costa, N., Bellacchio, E., Mattarocci, S., Fuiano, G., et al. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0525-5 · Cited by 103
Self-citation
Cited by
PI3K signaling in cancer: beyond AKT
Lien, E. C., Dibble, C. C., & Toker, A. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.02.007 · Cited by 451
Hochstetler, A., Smith, H., Reed, M., Hulme, L., Territo, P., Bedwell, A., Persohn, S., Perrotti, N., D’Antona, L., Musumeci, F., et al. (2023) · Fluids and Barriers of the CNS · doi:10.1186/s12987-023-00461-0 · Cited by 10
Self-citationComputational insights into the active structure of SGK1 and its implication for ligand design
Akhoon, B. A., Gandhi, N. S., & Pandey, R. (2019) · Biochimie · doi:10.1016/j.biochi.2019.07.007 · Cited by 9
Doyle, M. A., Bali, V., Eagle, A. L., Stark, A. R., Fallon, B., Neve, R. L., Robison, A. J., & Mazei-Robison, M. S. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01032-3 · Cited by 9
SGK-1 Signalling pathway is a key factor in cell survival in ischemic injury
Chaudhary, M., Sharma, V., Bedi, O., Kaur, A., & Singh, T. G. (2023) · Current Drug Targets · doi:10.2174/0113894501239948231013072901 · Cited by 6
Metadata
- Authors
- D''Antona, L., Amato, R., Talarico, C., Ortuso, F., Menniti, M., Dattilo, V., Iuliano, R., Gigliotti, F., Artese, A., Costa, G., Schenone, S., Musumeci, F., Abbruzzese, C., Botta, L., Trapasso, F., Alcaro, S., Paggi, M. G., & Perrotti, N.
- Venue
- Cellular Physiology and Biochemistry
- Publisher
- S. Karger AG
- Published
- 2015
- Volume
- 35
- Issue
- 5
- Pages
- 2006-2018
- ISSN
- 1015-8987 (ISSN-L)
- 1421-9778
- OpenAlex
- W1597699954
- Cited by
- 60
- References
- 3
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.